Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSR149744C · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| SSR149744C | DRUG | - |
Inclusion Criteria: * Patient with an ICD implanted during the previous year for documented spontaneous life-threatening ventricular arrhythmia OR implanted with an ICD and with at least one appropriate ICD therapy (shock or anti-tachycardia pacing) for ventricular tachycardia or ventricular fibril...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 5 | - | Undisclosed |
| Medtronic Plc | MDT | 1 | - | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | - | Undisclosed |
| HeartBeam, Inc. | BEAT | 1 | - | Undisclosed |
| Cardio Diagnostics Holdings Inc. | CDIO | 1 | - | Undisclosed |
SSR149744C is an investigational small molecule being studied for the prevention of ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, in patients with arrhythmia. It is being developed as a potential treatment to reduce arrhythmia-triggered ICD interventions.
SSR149744C is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its antiarrhythmic properties in the cardiovascular therapeutic area, with the goal of preventing ventricular arrhythmias.
SSR149744C is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical research to evaluate the safety and efficacy of this investigational drug for arrhythmia.
SSR149744C is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with ventricular arrhythmias.
SSR149744C has one completed Phase 2 clinical trial, identified as NCT00232297. This was a double-blind, placebo-controlled, dose-ranging study evaluating 100 mg and 300 mg doses of SSR149744C for the prevention of ventricular arrhythmia-triggered ICD interventions, enrolling 153 patients across multiple countries.
SSR149744C is the investigational code name for this drug. No alternative brand names or other designations have been disclosed for this compound in the available information.